



# SAFETY DATA SHEET

Revision date 16-Dec-2021

Version 2

Page 1 / 12

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

<b>Product Name</b>	Levetiracetam Injection (Hospira, Inc.)
<b>Product Code(s)</b>	PZ03336
<b>Trade Name:</b>	Not applicable
<b>Chemical Family:</b>	Mixture

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

<b>Recommended Use</b>	Pharmaceutical product used for electrolyte replacement
------------------------	---

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045 1-800-879-3477	Pfizer Ireland Pharmaceuticals OSG Building Ringaskiddy, Co. Cork. Ireland +353 21 4378701
<b>E-mail address</b>	pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

Emergency Telephone	Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
---------------------	---

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

### 2.2. Label elements

<b>Signal word</b>	Not Classified
--------------------	----------------

<b>Hazard statements</b>	Not classified in accordance with international standards for workplace safety.
--------------------------	---

### 2.3. Other hazards

<b>Other hazards</b>	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
----------------------	---

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 2 / 12  
Version 2

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

**Section 3: COMPOSITION/INFORMATION ON INGREDIENTS**

**3.1 Substances**  
**Substances**

Not applicable

**3.2 Mixtures**

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
+ ACETIC ACID (CAS #: 64-19-7)	**		200-580-7	Skin Corr. 1A (H314) Flam. Liq. 3 (H226)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1A :: C≥90% Skin Corr. 1B :: 25%≤C<90% Skin Irrit. 2 :: 10%≤C<25%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available
Levetiracetam (CAS #: 102767-28-2)	10		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified as hazardous	Not Listed	No data available	No data available
Sodium acetate trihydrate (CAS #: 6131-90-4)	**		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 3 / 12  
Version 2

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Levetiracetam 102767-28-2	> 5000	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
+ ACETIC ACID 64-19-7	3310	1060	11.4	No data available	No data available

## Additional information

+ Substance with a Union workplace exposure limit

\* Proprietary

\*\* to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians** None.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO<sub>2</sub>, alcohol-resistant foam or water spray.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Fine particles (such as mists) may fuel fires/explosions.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

### 5.3. Advice for firefighters

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 4 / 12  
Version 2

**Special protective equipment for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Not applicable.  
**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** None.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.  
**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.  
**Prevention of secondary hazards** None.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

#### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### SODIUM CHLORIDE

Latvia 5 mg/m<sup>3</sup>  
Russia MAC: 5 mg/m<sup>3</sup>

#### + ACETIC ACID

ACGIH TLV STEL: 15 ppm  
10 ppm  
Austria 10 ppm

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 5 / 12  
Version 2

---

	25 mg/m <sup>3</sup>
	STEL 20 ppm
	STEL 50 mg/m <sup>3</sup>
Bulgaria	STEL: 50 mg/m <sup>3</sup>
	STEL: 20 ppm
	25 mg/m <sup>3</sup>
	10 ppm
Czech Republic	25 mg/m <sup>3</sup>
	Ceiling: 50 mg/m <sup>3</sup>
Denmark	10 ppm
	25 mg/m <sup>3</sup>
Estonia	10 ppm
	25 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 25 mg/m <sup>3</sup>
European Union	50 mg/m <sup>3</sup> STEL; 20 ppm STEL
	25 mg/m <sup>3</sup> TWA; 10 ppm TWA
Finland	5 ppm
	13 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 25 mg/m <sup>3</sup>
France	25 mg/m <sup>3</sup>
Germany	10 ppm
	25 mg/m <sup>3</sup>
	Ceiling / Peak: 20 ppm
	Ceiling / Peak: 50 mg/m <sup>3</sup>
Germany	10 ppm
	25 mg/m <sup>3</sup>
Hungary	25 mg/m <sup>3</sup>
	STEL: 50 mg/m <sup>3</sup>
Ireland	20 ppm
	50 mg/m <sup>3</sup>
	STEL: 20 ppm
	STEL: 50 mg/m <sup>3</sup>
Italy	25 ppm
	10 mg/m <sup>3</sup>
	STEL: 50 mg/m <sup>3</sup>
	STEL: 20 ppm
Latvia	10 ppm
	25 mg/m <sup>3</sup>
	STEL: 50 mg/m <sup>3</sup>
	STEL: 20 ppm
Netherlands	25 mg/m <sup>3</sup>
	STEL: 50 mg/m <sup>3</sup>
Poland	STEL: 50 mg/m <sup>3</sup>
	25 mg/m <sup>3</sup>
Romania	10 ppm
	25 mg/m <sup>3</sup>
	STEL: 20 ppm
	STEL: 50 mg/m <sup>3</sup>
Russia	MAC: 5 mg/m <sup>3</sup>
	Skin
Slovakia	10 ppm
	25 mg/m <sup>3</sup>
Spain	10 ppm
	25 mg/m <sup>3</sup>
	STEL: 20 ppm
	STEL: 50 mg/m <sup>3</sup>
Switzerland	10 ppm
	25 mg/m <sup>3</sup>

---

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 6 / 12  
Version 2

OSHA PEL	STEL: 20 ppm STEL: 50 mg/m <sup>3</sup> 10 ppm 25 mg/m <sup>3</sup> (vacated) TWA: 10 ppm (vacated) TWA: 25 mg/m <sup>3</sup>
United Kingdom	TWA: 10 ppm TWA: 25 mg/m <sup>3</sup> STEL: 20 ppm STEL: 50 mg/m <sup>3</sup>

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

### Levetiracetam

Pfizer Occupational Exposure Band (OEB):

B-OEB 1 (control exposure to the range of  $\geq 10000 \mu\text{g}/\text{day}$ )

### SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB):

OEB 1 (control exposure to the range of  $1000\mu\text{g}/\text{m}^3$  to  $3000\mu\text{g}/\text{m}^3$ )

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Environmental exposure controls

No information available.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 7 / 12  
Version 2

## 9.1. Information on basic physical and chemical properties

<b>Physical state</b>	Solution
<b>Color</b>	Clear, colorless
<b>Odor</b>	No information available.
<b>Odor threshold</b>	No information available
<b>Molecular formula</b>	Mixture
<b>Molecular weight</b>	Mixture
<b><u>Property</u></b>	<b><u>Values</u></b>
<b>pH</b>	5.5
<b>Melting point / freezing point</b>	No data available
<b>Boiling point / boiling range</b>	
<b>Flash point</b>	No information available
<b>Evaporation rate</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Flammability Limit in Air</b>	
<b>Upper flammability limit:</b>	No data available
<b>Lower flammability limit:</b>	No data available
<b>Vapor pressure</b>	No data available
<b>Vapor density</b>	No data available
<b>Relative density</b>	No data available
<b>Water solubility</b>	No data available
<b>Solubility(ies)</b>	No data available
<b>Partition coefficient</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	No data available
<b>Kinematic viscosity</b>	No data available
<b>Dynamic viscosity</b>	No data available
<b>Particle characteristics</b>	
<b>Particle Size</b>	No information available
<b>Particle Size Distribution</b>	No information available
<b>Explosive properties</b>	No information available

## 9.2. Other information

No information available

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## **Section 10: STABILITY AND REACTIVITY**

### 10.1. Reactivity

**Reactivity** No data available.

### 10.2. Chemical stability

**Stability** Stable under normal conditions.

### Explosion data

**Sensitivity to Mechanical Impact** No data available.

**Sensitivity to Static Discharge** No data available.

### 10.3. Possibility of hazardous reactions

**Possibility of hazardous reactions** No information available.

### 10.4. Conditions to avoid

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 8 / 12  
Version 2

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions.

**10.5. Incompatible materials**  
**Incompatible materials** As a precautionary measure, keep away from strong oxidizers.

**10.6. Hazardous decomposition products**  
**Hazardous decomposition products** No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the individual ingredients

**Short term** Mild eye irritant in experimental animals (based on components)

**Acute toxicity** Based on available data, the classification criteria are not met.

**Serious eye damage/eye irritation** Based on available data, the classification criteria are not met.

**Skin corrosion/irritation** Based on available data, the classification criteria are not met.

**Respiratory or skin sensitization** Based on available data, the classification criteria are not met.

**STOT - single exposure** Based on available data, the classification criteria are not met.

**STOT - repeated exposure** Based on available data, the classification criteria are not met.

**Reproductive toxicity** Based on available data, the classification criteria are not met.

**Germ cell mutagenicity** Based on available data, the classification criteria are not met.

**Carcinogenicity** Based on available data, the classification criteria are not met.

**Aspiration hazard** Based on available data, the classification criteria are not met.

#### **Acute Toxicity: (Species, Route, End Point, Dose)**

##### **Levetiracetam**

Rat Oral LD50 > 5000 mg/kg  
Rat Para-periosteal LD50 > 1000 mg/kg

##### **SODIUM CHLORIDE**

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>  
Rat Oral LD 50 3 g/kg  
Mouse Oral LD 50 4 g/kg  
Rabbit Dermal LD 50 > 10 g/kg

##### **+ ACETIC ACID**

Mouse Sub-tenon injection (eye) LC 50 5620 ppm/1H  
Rat Oral LD 50 3310 mg/kg  
Rabbit Dermal LD 50 1060 uL/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
SODIUM CHLORIDE	= 3 g/kg ( Rat )	> 10000 mg/kg ( Rabbit )	> 42 mg/L ( Rat ) 1 h
+ ACETIC ACID	= 3310 mg/kg ( Rat )	= 1060 mg/kg ( Rabbit )	= 11.4 mg/L ( Rat ) 4 h

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### **Irritation / Sensitization: (Study Type, Species, Severity)**

##### **SODIUM CHLORIDE**

Skin irritation Rabbit Mild  
Eye irritation Rabbit Mild

#### **Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

##### **Levetiracetam**

6 Month(s) Rat Oral >= 50 mg/kg/day LOAEL Liver, Kidney, Central nervous system  
13 Week(s) Mouse Oral 60 mg/kg/day NOAEL Liver



# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 9 / 12  
Version 2

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Levetiracetam

Reproductive & Fertility Rat Oral 70 mg/kg/day NOAEL Fetotoxicity, Embryotoxicity  
Reproductive & Fertility Rat Oral 1800 mg/kg/day NOAEL Fertility  
Embryo / Fetal Development Rat Oral 3600 mg/kg/day NOAEL Maternal Toxicity  
Embryo / Fetal Development Rat Oral 1200 mg/kg/day NOAEL Fetotoxicity  
Embryo / Fetal Development Rabbit Oral 200 mg/kg/day LOAEL Maternal Toxicity  
Embryo / Fetal Development Rabbit Oral 200 mg/kg/day NOAEL Embryotoxicity  
Peri-/Postnatal Development Rat Oral 1800 mg/kg/day NOAEL Maternal Toxicity, Fetotoxicity

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Levetiracetam

*In Vitro* Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vitro* HGPRT Forward Gene Mutation Assay Chinese Hamster Ovary (CHO) cells Negative  
*In Vitro* Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative  
*In Vivo* Micronucleus Mouse Negative

## Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Levetiracetam

80 Week(s) Mouse Oral 960 mg/kg/day NOAEL Not carcinogenic  
104 Week(s) Rat Oral 1800 mg/kg/day NOAEL Not carcinogenic

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

### 11.2.2. Other information

**Other adverse effects** No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Releases to the environment should be avoided. Environmental properties of the formulation have not been investigated.

### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### + ACETIC ACID

Fathead Minnow NPDES LC-50 96 hours 88 mg/L  
Bluegill Sunfish NPDES LC-50 96 hours 75 mg/L  
Goldfish NPDES LC-50 24 hours 423 mg/L

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 10 / 12  
Version 2

**Mobility in soil** No information available.

## 12.5. Results of PBT and vPvB assessment

### **PBT and vPvB assessment**

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
+ ACETIC ACID	The substance is not PBT / vPvB PBT assessment does not apply

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

## 12.7. Other adverse effects

No information available.

## **Section 13: DISPOSAL CONSIDERATIONS**

### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## **Section 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

**UN number:** Not applicable  
**UN proper shipping name:** Not applicable  
**Transport hazard class(es):** Not applicable  
**Packing group:** Not applicable  
**Environmental Hazard(s):** Not applicable  
**Special precautions for user:** Not applicable

## **Section 15: REGULATORY INFORMATION**

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water  
**CERCLA/SARA Section 313 de minimus %** Not Listed  
**California Proposition 65** Not Listed  
**TSCA** Present

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 11 / 12  
Version 2

<b>EINECS</b>	231-791-2
<b>AICS</b>	Present
Levetiracetam	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 4
SODIUM CHLORIDE	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-598-3
<b>AICS</b>	Present
Sodium acetate trihydrate	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
<b>AICS</b>	Present
+ ACETIC ACID	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	200-580-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6 Schedule 2

**France**

**Occupational Illnesses (R-463-3, France)**

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

**European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

**Authorizations and/or restrictions on use:**

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
+ ACETIC ACID - 64-19-7	Use restricted. See item 75.	

**Persistent Organic Pollutants**

Not applicable

**Ozone-depleting substances (ODS) regulation (EC) 1005/2009**

Not applicable

**Plant protection products directive (91/414/EEC)**

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent
+ ACETIC ACID - 64-19-7	Plant protection agent

# SAFETY DATA SHEET

Product Name Levetiracetam Injection (Hospira, Inc.)  
Revision date 16-Dec-2021

Page 12 / 12  
Version 2

## Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## **Section 16: OTHER INFORMATION**

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### **Full text of H-Statements referred to under section 3**

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage. Flammable liquids-Cat.3; H226 - Flammable liquid and vapor.

**Data Sources:** Publicly available toxicity information.

**Reason for revision** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

**Revision date** 16-Dec-2021

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**